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Abstract
Background: Ovarian cancer (OvCa) most often derives from ovarian surface epithelial (OSE)
cells. Several lines of evidence strongly suggest that increased exposure to progesterone (P4)
protects women against developing OvCa. However, the underlying mechanisms of this protection
are incompletely understood.
Methods: To determine downstream gene targets of P4, we established short term in vitro
cultures of non-neoplastic OSE cells from six subjects, exposed the cells to P4 (10-6 M) for five days
and performed transcriptional profiling with oligonucleotide microarrays containing over 22,000
transcripts.
Results:  We identified concordant but modest gene expression changes in cholesterol/lipid
homeostasis genes in three of six samples (responders), whereas the other three samples (non-
responders) showed no expressional response to P4. The most up-regulated gene was TMEM97
which encodes a transmembrane protein of unknown function (MAC30). Analyses of outlier
transcripts, whose expression levels changed most significantly upon P4 exposure, uncovered
coordinate up-regulation of 14 cholesterol biosynthesis enzymes, insulin-induced gene 1, low
density lipoprotein receptor, ABCG1, endothelial lipase, stearoyl- CoA and fatty acid desaturases,
long-chain fatty-acyl elongase, and down-regulation of steroidogenic acute regulatory protein and
ABCC6. Highly correlated tissue-specific expression patterns of TMEM97  and the cholesterol
biosynthesis genes were confirmed by analysis of the GNF Atlas 2 universal gene expression
database. Real-time quantitative RT-PCR analyses revealed 2.4-fold suppression of the TMEM97
gene expression in short-term cultures of OvCa relative to the normal OSE cells.
Conclusion: These findings suggest that a co-regulated transcript network of cholesterol/lipid
homeostasis genes and TMEM97 are downstream targets of P4 in normal OSE cells and that
TMEM97 plays a role in cholesterol and lipid metabolism. The P4-induced alterations in cholesterol
and lipid metabolism in OSE cells might play a role in conferring protection against OvCa.
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Background
Ovarian cancer (OvCa), with a lifetime incidence of
approximately 1%, accounts for more deaths than all
other gynecologic malignancies combined [1]. Approxi-
mately 90% of OvCas originate from the ovarian surface
epithelium (OSE), a single layer of cuboidal cells covering
the ovaries [2]. Although many somatic gene defects have
been detected in OvCa, genetic alterations unique to
OvCa have been difficult to identify. Consequently, the
molecular mechanisms leading to OvCa remain amongst
the least understood of common cancers. Certain epide-
miological variables such as advancing age, low parity,
infertility, and family history are associated with increased
risk; whereas oral contraceptive use is associated with
decreased risk of OvCa [3]. Several biological models have
been advanced to explain the mechanisms of these risk-
modifying factors. The incessant ovulation hypothesis
postulates that repetitive wounding and healing of the
ovarian surface where the OSE cells proliferate to repair
the rupture during ovulation predisposes to OvCa by
leading to accumulation of mutations [4]. The gonadotro-
pin theory postulates that increased levels of pituitary
gonadotropins during ovulation and sustained high levels
during menopause stimulate production of estrogens and
other hormones to increase risk of OvCa. Although inces-
sant ovulation or chronic gonadotropin stimulation
could contribute to the etiopathogenesis of OvCa, it
appears that other hormonal factors such as androgenic
and progestogenic stimulations also play important
roles [5].
Risch [5] first proposed a protective role for progesterone
(P4) against OvCa on the bases of multiple lines of evi-
dence. First, the protective effect of pregnancies, and espe-
cially of twin pregnancies, against OvCa has been
attributed to the elevated levels of P4 in addition to the
suppression of ovulation [5], because the degree of pro-
tection conferred by pregnancies seems too high to be
explained simply by the pause in ovulation. Second, P4
reduces the proliferation rate in normal OSE cells both in
a primate model and in tissue culture [6-8] and suppresses
the transformed phenotype in vitro [9]. Third, P4 is a
potent inhibitor of proliferation in cultured human OSE
cells at concentrations similar to the levels reached during
pregnancy [10]. One potential mechanism for this protec-
tive effect is that high does of P4 could reduce invasive-
ness of OvCa by reducing epithelial membrane fluidity
[11]. Accordingly, it has been observed that pretreatment
of mice with P4 reduced the numbers of OvCa implants
in the abdominal cavity, whereas P4 treatment had no
effects once the tumors were implanted [12].
Despite evidence for an anti-carcinogenic role for P4 in
OvCa, it has been difficult to fully understand the under-
lying mechanisms. The intracellular effects of P4 are medi-
ated primarily by intracellular P4 receptors (PR) that are
expressed as two protein isoforms, PR-A and PR-B,
encoded by the same genetic locus [13]. The implicated
mechanisms underlying the protective effects of P4
against OvCa include induction of cell cycle arrest or
apoptosis, possibly through activation of the extrinsic
apoptotic pathway and Fas/FasL signaling, alternative
expression of transforming growth factor beta isoforms,
and alterations of the fluid dynamics of plasma mem-
branes in OvCa cells [14]. In a recent study, that analyzed
~2400 genes in OvCa lines, Syed et al.[15] found four sup-
pressed genes that were derepressed upon P4 exposure.
Depression of these genes suppressed the transformed
phenotype in OvCa cells. Although these studies have
provided clues for potential mechanisms of P4's anti-car-
cinogenic effects on OvCa cells, little is known about their
relevance for P4's prophylactic role against OvCa. In other
terms, mechanisms regulated by P4 that could prevent the
neoplastic transformation of normal OSE cells are
unknown.
To the best of our knowledge, no study has systematically
addressed the transcriptional impact of P4 on normal OSE
cells. In the light of strong epidemiological evidence
implicating P4 as a protective hormone against OvCa, it is
plausible that certain downstream effectors of P4 in nor-
mal OSE cells could be involved in protection against
OvCa. Here, we conducted a global survey of the expres-
sion changes induced by high concentrations of P4 expo-
sure for five days on normal OSE cells obtained from six
women. Our analysis, using Affymetrix oligonucleotide
microarray chips, revealed a coordinate and highly signif-
icant up-regulation of multiple genes in the cholesterol
and fatty acid biosynthesis pathways in response to P4.
Methods
Subjects and cell culture
Primary cultures of OSE cells were obtained following
informed consent from cases who underwent hysterec-
tomy and oophorectomy for various clinical indications
other than OvCa. In all cases the ovaries showed benign
alterations upon postoperative histological examination
(Table 1). Ovarian cancer samples were obtained from
Magee-Womens Hospital Tissue Bank. The research proto-
cols were approved by the University of Pittsburgh IRB
review committee.
The OSE cell cultures were established by brushing the
epithelial lining of the fresh ovaries. The epithelial con-
tent of the OSE cells were confirmed by immunofluores-
cence staining (Figure 1). Briefly, primary OSE cells were
spun onto slides using a cytospin centrifuge and fixed in
cold methanol at -20°C, and subjected to immunofluo-
rescence staining as described previously [16]. A mouse
monoclonal anti-cytokeratin antibody (clone K8.13,BMC Cancer 2007, 7:223 http://www.biomedcentral.com/1471-2407/7/223
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1:500 dilution, ICN, Irvine, CA) was used for cytokeratin
staining. Secondary antibody used was FITC-conjugated
goat anti-mouse IgG (Southern Biotechnology Associates,
Birmingham, AL). The nucleus was counterstained with
4',6'-diamidino-2-phenylindole (DAPI). The purity of the
epithelial component in each OSE cell culture for the six
cases were 100%, 100%, >90%, 90%, 100% and >80%,
respectively.
For P4 exposures, OSE cells were grown in Dulbecco's
Modified Eagle's Medium (DMEM) supplemented with
15% fetal bovine serum (FBS) and streptomycin/penicil-
lin. 48 hours before the hormone treatment, the OSE cells
were plated in four T25 flasks, the medium replaced with
DMEM supplemented with 15% charcoal-stripped FBS
and the cells allowed to reach 70–75% confluence. The
medium was then replaced with fresh media containing
Table 1: Clinical information for patients providing ovarian surface epithelium
Case Age Reason for surgery Final Diagnosis
1 45 Fibroid uterus Serosal adhesions and epithelial 
inclusions
2 74 Pelvic mass Serous cystadenofibroma
3 49 Prophylactic oopherectomy for 
sister had early-onset (38 y) 
ovarian cancer
Hemorrhagic follicular cysts
4 44 Menorrhagia and fibroids Follicular cysts
5 76 Endometrial cancer Epithelial inclusions
6 43 Pelvic mass Epithelial inclusions
Ovarian surface epithelial (OSE) cells in culture Figure 1
Ovarian surface epithelial (OSE) cells in culture. The epithelial origin of primary OSE cultures is demonstrated for one 
responder (case 2) and one non-responder cultures (case 5). a, cytokeratin staining, b, DAPI counterstain, c, merge of cytoker-
atin and DAPI staining. Magnifications: 10 × 20. The majority of OSE cultures expressed keratin, confirming their epithelial ori-
gin.
Case 2a Case 2b Case 2c
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10-6 M P4 (Sigma) or vehicle (ethanol). The final concen-
tration of ethanol in the media was 0.03% both in the P4
and control experiments. The hormone-treated cells were
exposed to P4 for a total of 5 days, with three fresh addi-
tions of media containing P4 (or vehicle) every 48 hours
for stable bioavailability as described [10]. At the end of
the fifth day, the medium was removed. The cells were
washed with PBS, collected following trypsin treatment
and immediately frozen for RNA extraction. Cells from
duplicate flasks were combined. To test bioavailability of
P4 in tissue culture, we used breast cancer cell line MCF-7
to confirm upregulation of human DLG5 gene by P4 [17]
and found 5.2-fold and 2.2-fold gene expression increases
by real-time RT-PCR at 8 and 24 hours, respectively.
RNA extraction
The total RNAs were extracted following a commercial
protocol (RNA-Bee, Tel-Test, Inc., Friendswood, TX) that
used phenol and guanidine thiocyanate. The total RNAs
were resuspended in DEPC-treated distilled water and fur-
ther purified using RNeasy mini-columns (Qiagen, Valen-
cia, CA) in preparation for microarray analyses. After
column purification, the total RNAs were quantitated by
absorbance at 260 nm using a Beckman DU-64 spectro-
photometer. Approximately 10 μg of total RNA were pro-
vided for microarray analysis of global gene expression
patterns. After the RNeasy™ purification step and demon-
strating an OD 260/280 ratio of 1.8 or higher, The Univer-
sity of Pittsburgh Microarray facility confirmed RNA
integrity via Agilent Bioanalyzer 2100.
Microarray hybridization and data processing
The high-density microarrays (Affymetrix gene chip type
U133A) used in this study contained 22,283 unique
human transcripts derived from the RefSeq database and
were commercially available from Affymetrix, Santa Clara,
CA. The hybridizations to microarrays were performed by
The University of Pittsburgh Microarray Facility. All RNAs
passed quality control tests before they were processed
further for microarray hybridizations. Afterwards, approx-
imately 5 μg of total RNA was used to generate double-
stranded cDNA by reverse transcription using a cDNA syn-
thesis kit (Superscript Choice System; Life Technologies,
Inc., Rockville, MD) that used an oligo(dT)24 primer con-
taining a T7 RNA polymerase promoter 3' to the poly T
(Geneset, La Jolla, CA), followed by second-strand synthe-
sis. Labeled cRNA was prepared from the double-stranded
cDNA by in vitro transcription by T7 RNA polymerase in
the presence of biotin-11-CTP and biotin-16-UTP (Enzo,
Farmington, NY). The labeled cRNA was purified over
RNeasy columns and hybridized to gene chips following
the manufacturer's protocol. cRNAs derived from the con-
trol unexposed cells and the P4 exposed cells were indi-
vidually hybridized to chips using identical experimental
protocols to reduce sources of technical variation.
Each transcript is represented on the chip as a set of 16–20
probe pairs with each pair containing a perfect match and
a mismatch. The mismatch is the same oligonucleotide as
the perfect match but with a single base substitution at the
central position. The amount of non-specific hybridiza-
tion is corrected by comparing the hybridization level
between the perfect match and the mismatch. Affymetrix
418 Array Reader was used to scan the fluorescently tagged
microarrays. Global scaling techniques were used for all
probe sets, to make the average intensity of each image
equal to an arbitrary target intensity, set to 150. The
expression data (signal intensities) across the chips were
normalized so that the expression levels of a gene were
directly comparable across the chips. The normalization
of all 12 chips was performed by D-chip software to the
probe level in the P4-exposed chip for sample#3, which
was arbitrarily chosen as the standard [18]. Results of the
genome-wide gene expression microarrays are submitted
to the public repository database, GEO: Gene Expression
Omnibus [19].
Quantitative RT-PCR (qRT-PCR) analyses
qRT-PCR was used to validate the up-regulation of genes
identified by microarray analysis using an ABI Prism 7700
Sequence Analyzer according to the manufacturer's rec-
ommendations (Applied Biosystems, Foster City, CA).
The comparative threshold cycle method was used for the
calculation of relative transcript amounts as specified by
the manufacturer. Complementary DNA was synthesized
with SuperScript II reverse transcriptase (RT) using total
RNA. qRT-PCR analysis of cDNAs for each gene included
a negative control template generated without addition of
reverse transcriptase during cDNA synthesis. Average fold
changes of target genes were determined relative to the
internal control genes. Each target and control gene was
amplified in separate wells in triplicates. The control
genes were chosen from among the housekeeping genes
whose expression levels did not change upon P4 exposure
in the microarray data. The probes for qRT-PCR were pur-
chased commercially from Applied Biosystems. PCR effi-
ciency tests were performed before the transcript
quantification assays to confirm that the amount of input
cDNA was inversely proportional to the threshold cycle
number for each gene (i.e. increased cDNA input reduced
the detection threshold in a linear fashion).
Expression and Genotyping of progesterone receptor (PR) 
Gene
PR gene polymorphisms are screened by standard PCR
amplification and restriction enzyme (RE) digestion. We
screened the V660L polymorphism by PCR amplifying PR
gene exon 4 by PCR oligonucleotide primers 5'-TTCTCT-
GTAGGTCGAAAATTTAAAA-3' and 5'-TATTATTACCT-
GGCAATGATTTAG-3' at an annealing temperature of
59°C and digesting with the BsrI RE. The allele for leucineBMC Cancer 2007, 7:223 http://www.biomedcentral.com/1471-2407/7/223
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destroys the BsrI RE site. Similarly, the +331 G/A SNP in
the promoter region was screened by PCR amplification
using oligonucleotide primers 5'-CACTACTGGGATCT-
GAGATC-3' and 5'-TTTATCTCCCGACTTTTTCTC-3' at an
annealing temperature of 55°C and NlaIV RE digestion.
The A allele destroys the NlaIV RE site. RE enzymes were
purchased from New England Biolabs (NEB). To investi-
gate the expression status of PR, we conducted real-time
qRT-PCR analysis using PR primers amplifying the tran-
script portion common to both the PR-A and PR-B iso-
forms and specific to the PR-B isoform in the P4-exposed
and baseline control cultures in samples 2,3 and 6. This
analysis showed that both isoforms of PR were expressed
in the responder and non-responders cell cultures without
significant changes upon P4 exposure (Additional File 1).
Statistical analysis
The normalized expression data from twelve chips were
analyzed jointly to detect genes and/or pathways regu-
lated by P4. The signal intensities of the transcripts in the
chips provide a quantitative measure of their relative
abundance. To assess gene expression changes upon P4
exposure, for each transcript, we calculated signal log ratio
(P4/control) in each of the six experimental pairs and
plotted the average of the six signal log ratios on the y-axis
against the average signal intensity in twelve chips on the
x-axis (Figure 2). The signal log ratio is a measure of fold
change in expression level for a transcript in the P4-
exposed sample relative to its unexposed control. The
change is expressed as the log2 ratio. A signal log ratio of 1
is the same as a 2-fold increase and signal log ratio of -1 is
the same as a 2-fold decrease in signal intensity of a tran-
script. We assumed that signal intensity of a transcript that
is not regulated by P4 would randomly fluctuate around a
mean value on repeated measurements. Therefore the
average signal log ratios of the six pairs would randomly
distribute on the y-axis close to zero. We also assumed
that signal intensities of transcripts expressed at similar
levels would show similar levels of variations, as strongly
suggested in Figure 2, on repeated measurements and
Genome-wide view of fold-change in gene expression by P4 exposure Figure 2
Genome-wide view of fold-change in gene expression by P4 exposure. Average of raw signals in 12 microarrays (x-
axis) are plotted against the average of log2-based fold-changes in expression in 6 microarray-pairs (y-axis) in the presence of 
10-6 M P4 for five days. 224 transcripts were statistically determined to be outliers (shown by triangles). Eleven of the outliers 
encode cholesterol biosynthetic enzymes (shown by plus signs). No transcript showed more than 2-fold average change (i.e., 
no points are dispersed beyond y = 1 or y = -1).
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therefore their average signal log ratios would also be
comparable. However, if a transcript is regulated by P4, its
average signal intensity would be displaced towards
higher (up-regulation) or lower (down-regulation) mean
values on the x-axis and its average signal log ratio would
be dispersed further away from zero on the y-axis relative
to the other transcripts of similar signal intensity, which
are not regulated by P4. We refer to the transcripts with the
most extreme average signal log-ratios (on y-axis) com-
pared to those transcripts expressed at similar levels as out-
liers and evaluate them as candidates for regulation by P4.
Different approaches to identify the outlier transcripts are
conceivable. For example, distribution of signal log ratios
for all transcripts can be approximated by continuous
curves that define significance boundaries [20]. Here, we
first ranked the transcripts on the basis of their average sig-
nal intensities in all 12 chips and generated a group from
every consecutive 500 transcripts. The grouping of tran-
scripts with similar expression levels safeguarded against
preferential selection of lowly expressed transcripts which
showed greater variations in their signal log ratios. As
expected, the signal log ratios of all transcripts distributed
symmetrically around the x-axis (Figure 2). Then, starting
with the most abundantly expressed transcripts, we found
the transcripts whose average signal log ratios were most
extreme within each group of 500 transcripts. We found
the transcripts whose average signal log ratios were
located more than 3 standard deviations (SD) away from
the mean of the group and whose fold changes were
located more than 2 interquartile regions (iqr) away from
the first and third quartile of the group. We defined these
transcripts as outliers. In a normal distribution, 99% of
the data points fall within three SDs of the mean. Whereas
the 2iqr limits around the median delimits moderate out-
liers in any distribution. These two measures of dispersion
were jointly used to detect the outlier transcripts at a mod-
erate stringency level even if the distribution of signal-log
ratios may not be normal in a group.
The outlier transcripts were then submitted to the Affyme-
trix web site [21] to identify biological pathways and clus-
ters listed in the Gene Ontology database associated with
the outlier transcripts. No particular pathway or cluster
was expected to be significantly enriched by the outlier
transcripts under the null hypothesis. To test this hypoth-
esis, we conducted one-sided two-by-two Fisher's exact
test [22] for enrichment of each of the pathways or clus-
ters by the outliers. The total number of annotated (i.e.,
assigned to a pathway) outliers and the total number of
annotated non-outliers were constant entries in each
Fisher's exact test, whereas the numbers of outlier and
non-outlier transcripts in a specific biological pathway/
cluster were entered as variable values. We implemented
two conservative measures to the serial significance testing
of pathways for enrichment. First, the number of outlier
transcripts belonging to a pathway was reduced by 1, as
the first outlier transcript hit to a pathway was designated
as the "ascertaining transcript" which could be a chance
ascertainment. This step eliminated from further testing
all pathways represented by only one transcript. Second,
because some pathways were expected to show significant
enrichment by chance as a result of multiple testing, we
performed a Bonferroni correction and multiplied the
nominal p-values by the total number of pathways ascer-
tained by the outliers before declaring significance.
Results
Analysis of gene expression changes in OSE cells upon P4 
exposure
The OSE cultures derived from six women (Table 1) were
exposed to P4 (10-6 M) for five days and gene expression
changes were profiled in P4-exposed and baseline control
cultures using U133A Affymetrix chips. These exposure
conditions were chosen because comparable serum P4
levels (~552 nM) are reached at term in normal pregnan-
cies [23] and because five days of exposure to 10-6 M P4
slows down proliferation in OSE cells in vitro [10]. Thus
these conditions were likely to mimic the physiological
effects of long-term P4 exposure. The average signal inten-
sities obtained from 12 normalized chips plotted against
average signal-log ratios of the expressional changes from
six experimental pairs are shown for 22, 283 transcripts in
Figure 2 (also see methods). Transcripts expressed at
lower levels showed more variation than the ones
expressed at higher levels (Figure 2). The dependence of
signal-log ratios, which is a measure of fold-change, on
signal intensity was previously recognized [24], and is
attributed to small random changes in signal intensities
which could inflate fold-changes in less abundant tran-
scripts than they would do in highly expressed genes. To
lessen the impact of this artifact, 853 of the most-weakly
expressed transcripts (~3.8% of all transcripts), which fell
below an arbitrary signal intensity cutoff level of 50, were
removed from further analysis. The remaining 21,430
transcripts were evaluated further for gene expression
changes upon P4 exposure.
Outlier detection and pathway analysis
The average of the signal log ratios in six experimental
pairs revealed that no transcript showed a change in gene
expression level more than two-fold upon P4 exposure
(Figure 2). To determine smaller but statistically signifi-
cant gene expression changes, we evaluated 224 tran-
scripts (outliers) that showed the greatest fold-changes in
gene expression upon P4 exposure relative to the tran-
scripts expressed at similar levels. Next, we tested whether
these outlier transcripts were enriched for any of the bio-
logical pathways/clusters listed in The Gene Ontology
database (see methods). One hundred sixty seven of theBMC Cancer 2007, 7:223 http://www.biomedcentral.com/1471-2407/7/223
Page 7 of 13
(page number not for citation purposes)
outlier transcripts were annotated to a cellular pathway or
cluster. These annotated outlier transcripts belonged to
551 biological pathways (Table 2). Although no particular
pathway is expected to be enriched by the outlier tran-
scripts (null hypothesis), we found that several metabolic
pathways involving lipid biosynthesis were significantly
overrepresented by the outlier transcripts (Table 2). The
most significant enrichment was found in the cholesterol
biosynthesis pathway: eleven of the 36 transcripts in this
pathway were present among the outliers, although none
(0.4) was expected under the null hypothesis (Figure 2).
These eleven transcripts, encoding seven enzymes in the
cholesterol biosynthesis pathway, were also responsible
for the significant enrichment of other lipid metabolism
pathways (Table 2).
Distinct responses of OSE cells to P4
An inspection of the gene expression changes in the
eleven outlier transcripts in the cholesterol biosynthesis
pathway in each experimental pair revealed that whereas
the cultures derived from cases 1, 2 and 4 (responder
group) showed consistent up-regulation of these tran-
scripts, the other three cultures (non-responder group)
did not show appreciable changes in the transcript levels.
This finding prompted us to analyze the outlier transcripts
of the two groups separately. The responder group had 18
upregulated outlier transcripts encoding 11 genes in the
Table 2: Biologic pathways and clusters enriched by the outlier transcripts
Gene Ontology 
Term
Annotated 
transcripts on 
array
Annotated 
transcripts in 
outliers (all 6 
cases)
aP-values (6 
cases)
Annotated 
transcripts in 
outliers (3 
responder 
cases)
bP-values (3 
responder 
cases)
cAnnotated 
transcripts in 
outliers (3 non-
responder 
cases)
All pathways 
and clusters
15 047 167 -- 188 -- 94
Lipid 
metabolism
754 21 NS 30 2.76 × 10-4 4
Cellular lipid 
metabolism
602 18 NS 29 9.65 × 10-6 3
Lipid 
biosynthesis
255 17 3.93 × 10-5 28 1.33 × 10-13 3
Alcohol 
metabolism
324 11 NS 23 3.44 × 10-7 0
Steroid 
metabolism
198 12 1.17 × 10-2 24 2.36 × 10-12 1
Steroid 
biosynthesis
90 12 4.47 × 10-6 23 5.58 × 10-19 1
Sterol 
metabolism
93 11 7.12 × 10-5 21 5.46 × 10-16 0
Sterol 
biosynthesis
44 11 3.07 × 10-8 20 9.91 × 10-22 0
Cholesterol 
metabolism
85 11 3.01 × 10-5 19 3.58 × 10-14 0
Cholesterol 
biosynthesis*
36 11 4.13 × 10-9 18 3.50 × 10-20 0
Isoprenoid 
metabolism
18 5 2.39 × 10-2 73 . 7 3  ×  1 0 -5 0
Isoprenoid 
biosynthesis
16 5 1.45 × 10-2 71 . 6 5  ×  1 0 -5 0
Mitotic cell 
cycle
319 4 NS 15 4.61 × 10-2 0
Nuclear division 268 2 NS 14 2.97 × 10-2 0
M phase of 
mitotic cell 
cycle
213 2 NS 14 2.70 × 10-3 0
Mitosis 209 2 NS 14 2.20 × 10-3 0
Phosphate 
transport
106 8 NS 10 5.30 × 10-3 0
a Fisher's exact test, corrected for multiple pathway testing (n = 551).
b Fisher's exact test, corrected for multiple pathway testing (n = 542).
c No significant enrichment for any of the 449 pathways.
NS: Not significantBMC Cancer 2007, 7:223 http://www.biomedcentral.com/1471-2407/7/223
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cholesterol biosynthesis pathway, whereas the non-
responder group had no significant enrichment for any
biological pathway (Table 2). A full list of outlier tran-
scripts detected in the three responder cases is provided in
Additional File 3.
TMEM97, encoding a transmembrane protein of
unknown function (MAC30), showed the highest fold-
change (1.94-fold, Additional File 3) among the upregu-
lated outlier transcripts in the responder group. TMEM97
was first identified as a downregulated gene in meningi-
oma [25] and was later found to be transcriptional target
of the BRCA1 gene [26]. TMEM97 is strongly expressed in
the pancreas and other gastrointestinal tissues and is
downregulated in pancreatic cancer [27].
The presence of 18 transcripts encoding 11 genes in the
cholesterol biosynthesis pathway among the outlier tran-
scripts of the responder group further prompted us to
evaluate the expressional changes of other genes in the
cholesterol biosynthesis pathway (Figure 3). We found
that transcripts encoding lanosterol synthase, sterol-C4-
methyl oxidase-like, and sterol C5 desaturase were also
among the outliers (Additional File 2) although they were
annotated as part of steroid or sterol biosynthesis, but not
cholesterol biosynthesis in the Gene Ontology database.
An overview of the cholesterol biosynthesis pathway Figure 3
An overview of the cholesterol biosynthesis pathway. The enzymes whose transcripts are upregulated upon P4 expo-
sure are shown by asterisks. The full names of the gene symbols are listed in Additional File 2. The cholesterol is synthesized 
from acetyl-CoA. HMGCR is the rate limiting enzyme because reduction of 3-hydroxy-3-methylglutaryl CoA to mevalonate is 
the committed step in cholesterol formation. Mevolanate is converted to isopenthenyl pyrophosphate by three sequential 
reactions requiring ATP. Then squalene is synthesized from six molecules of isopenthenyl pyrophosphate. Then squalene epox-
ide is cyclized to lanosterol which is converted into cholesterol. The carbon numbers of some intermediates are shown in 
parenthesis. P4 upregulates transcripts encoding enzymes located throughout the complex biosynthetic pathway. Whereas 
PRKAA1/2, PRKAB1/2, PRKAG1/2, the genes for subunits of AMP-dependent protein kinase (AMPK), which inhibits HMGCR, 
appear not to be regulated by P4 (Additional File 2).
Acetyl-CoA (C2) 
+ 
Acetoacetyl-CoA (C4) 
3-hydroxy-3-methyl-glutaryl CoA
(C6)
Mevalonate
HMGCR*
Mevalonate-5-phosphate
Mevalonate-5-pyrophosphate
HMGCS1*,
HMGCS2
MVK*
PMVK
MVD Δ3-isopentenyl pyrophosphate
(C5)
IDI1*
Dimethyl-allyl pyrophosphate
AMPK 
(PRKAA1/2, PRKAB1/2, PRKAG1/2)
Geranyl pyrophosphate
(C10)
Farnesyl pyrophosphate
+
Farnesyl pyrophosphate
(C15)
FDFT1*
FDPS*, 
GGPS1
Squalene (C30)
Squalene-2,3-epoxide
SQLE,
SEC14L1
LSS*
Lanosterol 14-Demethyl lanosterol
CYP51A*
Cytochrome b5(DIA1)
Dimethylcholesta-8,24-dien-3β-ol
TM7SF2
SC4MOL*
Carboxymethylcholesta-
8,24-dien-3β-ol
NSDHL* Monomethylcholesta-
8,24-dien-3β-ol
NSDHL*
SC4MOL*
Zymosterone
HSD17B7
EBP*
Zymosterol 
(Cholesta-8,24-dien-3β-ol)
Cholesta-7,24-dien-3β-ol Lathosterol
DHCR24
Cholest-8(9)-en-3β-ol
DHCR24
7-Dehydrodesmosterol 7-Dehydrocholesterol
SC5D*
EBP*
DHCR24
DHCR7*
Desmosterol
SC5D*
DHCR7*
Cholesterol
(C27)
DHCR24
FDPS*, 
GGPS1
ACAT2*BMC Cancer 2007, 7:223 http://www.biomedcentral.com/1471-2407/7/223
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Inclusion of these genes brought the total number of
upregulated genes in the cholesterol biosynthesis pathway
to 14. In addition, transcripts for other cholesterol biosyn-
thesis genes such as squalene epoxidase were also upregu-
lated in the responder group, although they were not
detected as outliers (Additional File 2).
The profound impact of P4 on cholesterol metabolism
was also evident by transcriptional regulation of other
important genes in cholesterol metabolism. Insulin
induced gene-1 (INSIG-1), low density lipoprotein recep-
tor (LDLR), and ATP-binding cassette transporter G1
(ABCG1) were upregulated; steroidogenic acute regula-
tory protein (StAR) and ATP-binding cassette transporter
C6 (ABCC6) were downregulated (Additional File 2). In
addition, several genes involved in fatty acid metabolism
including fatty acid desaturases 1 and 2 (FADS1 and 2),
stearoyl-CoA desaturase (SCD), endothelial lipase, phos-
pholipase A2, group IVA, long-chain fatty-acyl elongase,
cytochrome P450, subfamily IIC, polypeptide 18 were
among the outlier transcripts (Additional File 2).
Confirmation of transcriptional up-regulation by 
quantitative RT-PCR (qRT-PCR)
To confirm the transcriptional up-regulation of outlier
transcripts in the microarray data, we selected TMEM97
and three upregulated genes in the cholesterol biosynthe-
sis pathway: HMG CoA reductase (HMGCR), the rate-lim-
iting enzyme in the cholesterol biosynthesis, isopentenyl-
diphosphate delta isomerase (IDI1) and 7-dehydrocho-
lesterol reductase (DHCR7) for additional analyses. We
used two genes as controls, small nuclear ribonucleopro-
tein 70 kDa polypeptide (SNRP70) and ubiquitin car-
boxyl-terminal esterase L3 (UCHL3), which were
expressed at similar levels to the tested genes but whose
expressional levels did not change upon P4 exposure in
the microarray data. For all four tested genes, the real-time
quantitative RT-PCR analysis showed expressional
changes similar to the microarray results in two responder
(cases 2,4) and one non-responder sample (case 6)
(Table 3).
Progesterone receptor (PR) status in the responder and 
non-responder cases
We explored whether genetic differences in the PR could
explain the differential response to P4 in the responder
and non-responder OSE cell cultures. It has been sug-
gested that certain genetic polymorphisms in the PR gene
could modify the transcriptional activity of the PR
[28,29]. These SNPs were V660L, which tags a distinct
haplotype known as PROGINS, and +331 G/A, a SNP
located in the promoter region. The responder case 2 was
heterozygous for both SNPs, whereas the other five cases
were homozygous G/G-V/V. Thus, the genotypes of the
two SNPs were not significantly different between the
responder and non-responder cases. To investigate the
expression status of PR, we conducted real-time qRT-PCR
analysis using PR primers amplifying the transcript por-
tion common to both the PR-A and PR-B isoforms and
specific to the PR-B isoform in the P4-exposed and base-
line control cultures. This analysis showed that both iso-
forms of PR were expressed in the responder and non-
responders cell cultures without significant changes upon
P4 exposure (Additional File 1).
Tissue-specific expression levels of TMEM97 correlate 
with cholesterol biosynthesis genes
To determine whether co-expression of TMEM97 and cho-
lesterol biosynthesis genes also occurs in other normal tis-
sues, we analyzed tissue-specific expression levels in the
GNF Gene Expression Atlas2 database [30] using UCSC
Genome Browser's Gene Sorter utility [31]. The Gene
Sorter ranks 20,161 human genes based on their differ-
ence in tissue-specific expression levels relative to a
selected gene, which was ranked at number 1, using data
from multiple tissues including fetal brain, whole brain,
amygdala, thymus, bone marrow, CD4+ peripheral blood
cells, adipocyte, pancreatic isles, heart, lung, kidney, liver,
ovary and testes. When TMEM97 was ranked at number 1,
farnesyl diphosphate synthase (FDPS), farnesyl-diphos-
phate farnesyltransferase (FDFT1) and acetyl-CoA acetyl-
transferase 2 (ACAT2) genes were ranked, at numbers 10,
34 and 43, respectively, among the top 50 genes that have
Table 3: qRT-PCR confirmation of gene regulation (fold-change) with P4 exposure
Case HMGCR DHCR7 IDI1 MAC30 Average fold-change 
in four genes
2a 1.87 1.72 1.98 2.65 2.06
4a 1.27 1.44 1.87 * 1.53
6b 0.98 0.97 0.87 0.87 0.92
a responder sample in microarray analysis
b non-responder sample in microarray analysis
*: RNA used in the microarray hybridizations was not available for this test.BMC Cancer 2007, 7:223 http://www.biomedcentral.com/1471-2407/7/223
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the closest tissue-specific expression levels (last column in
Additional File 2). The ranking of 3 of the 23 cholesterol
biosynthesis genes among the top 50 genes is highly unex-
pected (expected number = 0.06, observed number = 3;
Poisson p-value = 0.00003). Alternatively, the ranking of
18 cholesterol biosynthesis genes among the top 5000 is
also highly unexpected (expected number = 6, observed
number = 18; Fisher's exact test = 0.00047). These results
support our conclusions derived from the microarray
analyses of OSE cells in that the expression of TMEM97 is
co-regulated with cholesterol biosynthesis genes in nor-
mal tissues.
Evaluation of TMEM97 in ovarian cancer
Because somatic alterations in downstream targets of P4
in OSE cells could play a role in the pathogenesis of OvCa,
we compared the expression of TMEM97 in normal OSE
cells and OvCa cells that are maintained in the short-term
culture and harvested for RNA extraction under identical
conditions. We evaluated the expression of TMEM97 in
OvCa samples and in normal OSE cells relative to the con-
trol genes using real-time quantitative RT-PCR. Compared
to the normal OSE cells, the OvCa samples showed 2.71-
and 2.22-fold reduced expression of TMEM97  when
SNRP70 and GAPDH were used as control genes, respec-
tively (Table 4).
To test for somatic mutations in the TMEM97 gene, which
is located on chromosome band 17q11.2, we sequenced
all of the coding nucleotides (528 base pairs), that are dis-
tributed to three exons, in 39 ovarian cancer samples. We
found an intronic single nucleotide polymorphism (IVS1
+12 C>T) in a single sample but no coding sequence vari-
ations.
Discussion
To determine the intracellular gene targets of P4 in non-
neoplastic OSE cells, we analyzed changes in gene expres-
sion patterns in six independent short-term cultures using
genome-wide transcript arrays. We found a highly statisti-
cally significant regulation of transcripts involved in cho-
lesterol metabolism. For example, multiple transcripts
representing cholesterol-homeostasis genes including
HMGCS1, HMGCR, IDI1, FDPS, FDFT1, NSDHL, EBP,
DHCR7, INSIG1, FADS1 were upregulated by P4 exposure
(Additional File 2). Examination of each experimental
pair revealed that the transcriptional activity induced by
P4 exposure originated only from three of the six experi-
mental pairs. Re-analysis of these three responder pairs
uncovered a functionally uncharacterized gene TMEM97
as the most-responsive transcript which showed a 1.95-
fold increase upon P4 exposure. Examination of genome-
scale, tissue-specific gene expression levels in the GNF2
database uncovered a strong correlation between
TMEM97 and cholesterol biosynthesis genes. This finding
and our current microarray analyses suggest that TMEM97
plays a role in cholesterol metabolism. We also found that
the expression of TMEM97 was downregulated ~2.4-fold
in OvCa samples. Collectively, these findings suggest that
P4 is involved in cholesterol metabolism in OSE cells. To
our knowledge, P4-regulation of cholesterol homeostasis
genes in OSE cells has not been previously suggested. An
earlier work has shown suppression of a subset of the cho-
lesterol biosynthesis pathway genes by PR receptor inhib-
itors in rat periovulatory granulose cells suggesting that P4
regulation of cholesterol homeostasis could be, at least in
part, receptor-mediated [32].
The lack of significant gene expression changes in three of
the six experimental pairs suggests that the transcriptional
response to P4 may not be universal among OSE cells, at
least under the experimental conditions described herein.
The reasons for this differential response are currently
unclear. Analyses of two genetic polymorphisms and the
expression of PR gene did not reveal appreciable differ-
ences between the responder and non-responder groups.
Certain clinical characteristics such as history of oral con-
traceptive use, serum gonadotropin, estrogen or proges-
terone levels at the time of surgery might have influenced
the responsiveness of the OSE cells to P4. However,
because the OSE cells remained in culture under identical
conditions for at least two weeks before the experiments,
it is unlikely that any reversible in vivo effects of these hor-
mones would persist when the cells were treated with P4.
Alternatively, certain constitutional or somatically-
induced genetic changes might affect the P4-responsive-
ness of certain OSE cells. Notably, one of the three non-
responder OSE cells was derived from a subject (case # 3)
Table 4: qRT-PCR analysis of TMEM97 expression in ovarian cancer (OvCa) relative to normal ovarian surface epithelial (OSE) cells
Control gene ΔCT in OSE (n, SE) ΔCT in OvCa (n, SE) ΔΔCT (OvCa-OSE) *Fold-change of TMEM97 
(suppression in OvCa)
GAPDH 7.86 (5, 0.48) 9 (28, 0.29) 1.14 2.204
SNRP70 -1.30 (8, 0.90) 0.14 (21, 0.52) 1.44 2.713
ΔCT = Average cycle threshold difference between TMEM97 and the control gene
n = number of samples
SE = standard error of the mean
*Fold-change in expression = 2ΔΔCTBMC Cancer 2007, 7:223 http://www.biomedcentral.com/1471-2407/7/223
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whose ovaries were removed because of her sister's history
of early-onset ovarian cancer (Table 1). A second non-
responder sample (case # 5) was derived from a subject
with endometrial cancer, which sometimes co-occurs with
OvCa [33]. Thus, whether mutations increasing suscepti-
bility to OvCa could blunt responses to P4 remains to be
investigated. Although hormonal and/or genetic factors
might affect the responsiveness of certain OSE samples to
P4, our data indicate that at least certain OSE samples
clearly show a broad transcriptional regulation of choles-
terol homeostasis genes upon P4 exposure. Thus, poten-
tial impact of cholesterol metabolism on the pathogenesis
of OvCa should be considered.
Our data suggest that the impact of P4 on cholesterol
metabolism is profound and involves broad transcrip-
tional regulation of many genes regulating cholesterol
and lipid biosynthesis and transport. The P4-induced
transcriptional changes in most genes in cholesterol
metabolism predict an increase in intracellular cholesterol
levels. These changes include (a) up-regulation of 14
enzymes catalyzing both early and late steps of de novo
biosynthesis (b) up-regulation of the low density lipopro-
tein receptor and ATP-binding cassette (ABC) transporter
ABCG1  genes [34], which predict increased cellular
uptake and (c) reduced conversion to gonadal and adre-
nal steroids by down-regulation of the StAR gene [35]. It
is conceivable that increased cholesterol synthesis could
compensate for the downregulation of StAR and lead to
increased OSE steroid synthesis. Similarly, the P4-induced
transcriptional up-regulation of genes involved in unsatu-
rated fatty acid metabolism predicts an increased synthe-
sis of unsaturated fatty acids. Whereas the up-regulation
of stearoyl-CoA and fatty acid desaturases predicts an
increased  de novo synthesis [36], up-regulation of the
phospholipase A2 gene PLA2G4A and endothelial lipase
[37] may promote release of unsaturated fatty acids such
as oleic acid and arachidonic acid from membrane phos-
pholipids. Similarly, down-regulation of cytochrome
P450 gene CYP2C18 [38] might help reduce conversion of
arachidonic acid to other biologically active eicosanoids.
Cholesterol and fatty acids are essential components of
the cell membrane [39]. Thus, the P4-induced changes in
cholesterol and lipid metabolism might influence such
physicochemical characteristics of the OSE cell membrane
as fluidity. OSE cells remain physically intact during preg-
nancy and the secretory phase of the menstrual cycle,
when P4 levels are high and no ovulation occurs. Perhaps,
in these physiological states, an increase in the cholesterol
content of OSE cell membrane induced by P4 might
decrease membrane fluidity and help maintain the physi-
cal integrity of the OSE cells that cover the ovary. Notably,
inhibitory effects of P4 on membrane fluidity of SKOV-3
ovarian adenocarcinoma cells has been independently
suggested and linked to decreased tumorigenic behavior
of P4-treated OvCa cells [11]. The present results suggest
that increased cholesterol biosynthesis might underlie the
decreased membrane fluidity observed in SKOV-3 cells.
The current findings might be further interpreted to sug-
gest that defects in the P4-induced cholesterol biosynthe-
sis pathway might increase vulnerability of OSE cells to
inflammatory or physical damage and increase the risk of
neoplastic transformation. Accordingly, we found that
TMEM97, the most upregulated gene by P4 in our dataset,
was coordinately expressed with cholesterol biosynthesis
genes in other tissues and was suppressed 2.4-fold in the
OvCa samples relative to normal OSE cells. Further exper-
iments including evaluation of the expressional status of
other cholesterol biosynthesis genes and functional stud-
ies of cholesterol metabolism genes by employing such
experimental approaches as siRNA inhibition of the can-
didate genes in OvCa cells might help to understand
whether alterations in cholesterol homeostasis plays a
general role in pathogenesis of ovarian cancer.
Conclusion
The present results suggest that TMEM97 and cholesterol
and lipid homeostasis genes are transcriptional targets of
P4 in normal OSE cells. If confirmed, these results could
provide new insights on the molecular steps involved in
the development of OvCa.
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